Cancer detection kit, which fuses molecular diagnostics with nanotechnology

Acrongenomics Inc. has introduced a revolutionary design of its nanobiotechnology product, the Neo-EpCAM(TM) cancer detection kit, which fuses molecular diagnostics with nanotechnology.

The Neo-EpCAMTM kit will be used for the detection of cancers of epithelial origin such as, lung, breast, colon, prostate, head and neck, stomach, ovary, pancreas, oesophagus, and larynx.

The Neo-EpCAM(TM) cancer detection kit can be performed on the most commonly used technological platform, the PCR (Polymerase Chain Reaction), for molecular diagnostics. The never-before-seen rapidity in molecular diagnostics will now have the advantage of increased sensitivity and specificity. The diagnostic test can be performed by personnel already trained and familiar with the PCR, and does not require additional scientific skills.

The technology dramatically reduces lab result time and labour costs by up to 75%, thereby substantially increasing productivity to all diagnostic centers and laboratories. As a result, this significant improvement offers patients better service and benefits.

Progress on Neo-EpCAMTM evaluation studies has brought Acrongenomics one step closer to the development of a commercial product.